Cancer Chemotherapy and Pharmacology

, Volume 65, Issue 1, pp 67–71

Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients

Authors

    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • Naiyer Rizvi
    • Thoracic Oncology ServiceMemorial Sloan-Kettering Cancer Center
  • Gary Deng
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • K. Simon Yeung
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • Andrew Vickers
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
    • BiostatisticsMemorial Sloan-Kettering Cancer Center
  • Stacey Guillen
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • Derek Woo
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • Marci Coleton
    • Integrative Medicine ServiceMemorial Sloan-Kettering Cancer Center
  • Mark G. Kris
    • Thoracic Oncology ServiceMemorial Sloan-Kettering Cancer Center
Original Article

DOI: 10.1007/s00280-009-1003-z

Cite this article as:
Cassileth, B.R., Rizvi, N., Deng, G. et al. Cancer Chemother Pharmacol (2009) 65: 67. doi:10.1007/s00280-009-1003-z

Abstract

Purpose

To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC.

Methods

Patients with advanced NSCLC who progressed after prior platinum-containing chemotherapy were accrued and received docetaxel at 35 mg/m2 for 3 weeks followed by 1 week of rest. At 4 days prior to the second dosing, Jinfukang was given orally. Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared.

Results

Of the 24 patients enrolled, 21 started Jinfukang and docetaxel. Jinfukang had no significant impact on the pharmacokinetics of docetaxel. Median time to progression or withdrawal from treatment was 7 weeks. Twelve patients were removed from study for progression of disease; nine patients withdrew.

Conclusions

Jinfukang did not alter the pharmacokinetics of docetaxel nor appear to affect survival in this study.

Keywords

Lung cancerChemotherapyDocetaxelBotanicalsAstragalus

Copyright information

© Springer-Verlag 2009